BUSINESS: Roche acquires Genentech for $46.8B


Leading biotech company Roche, parent company of Roche Molecular Diagnostics in Pleasanton, annouced yesterday that it has reached an agreement to purchase San Francisco-based Genentech for $46.8 billion.

The merger means Swiss drugmaker Roche will acquire Genentech for $95 per share.

In a statement released by Roche, the company says the merger will make Roche the seventh largest U.S. pharmaceuticals company in terms of market share. The combined company's U.S. commercial operations in pharmaceuticals will operate under the Genentech name.

Roche is a world leader in in-vitro diagnostics and drugs for cancer and transplantation.

--Janet Pelletier

We can't do it without you.
Support local journalism.


Sorry, but further commenting on this topic has been closed.

Don't be the last to know

Get the latest headlines sent straight to your inbox every day.

Talking sports and life with Tommy Dyer
By Tim Hunt | 1 comment | 1,476 views

Couples: Thanks
By Chandrama Anderson | 0 comments | 475 views